{"protocolSection":{"identificationModule":{"nctId":"NCT01441440","orgStudyIdInfo":{"id":"B2411263"},"organization":{"fullName":"Pfizer","class":"INDUSTRY"},"briefTitle":"Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)","officialTitle":"A Randomized, Double-blind, Placebo Controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Venlafaxine Er In Adult Outpatients With Major Depressive Disorder"},"statusModule":{"statusVerifiedDate":"2015-03","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2011-11"},"primaryCompletionDateStruct":{"date":"2014-03","type":"ACTUAL"},"completionDateStruct":{"date":"2014-03","type":"ACTUAL"},"studyFirstSubmitDate":"2011-09-23","studyFirstSubmitQcDate":"2011-09-23","studyFirstPostDateStruct":{"date":"2011-09-27","type":"ESTIMATED"},"resultsFirstSubmitDate":"2015-03-02","resultsFirstSubmitQcDate":"2015-03-02","resultsFirstPostDateStruct":{"date":"2015-03-13","type":"ESTIMATED"},"lastUpdateSubmitDate":"2021-01-26","lastUpdatePostDateStruct":{"date":"2021-01-28","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"This is a phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of venlafaxine ER 75 mg/day (fixed dose) and venlafaxine ER 75 mg/day to 225 mg/day (flexible dose), compared to placebo. This study consists of 2 week screening phase, 8 week treatment phase and 2 week tapering phase. The follow-up visit will be evaluated after 2 weeks of last study medication dosing."},"conditionsModule":{"conditions":["Major Depressive Disorder"],"keywords":["venlafaxine ER","Major depressive disorder","Japan","placebo-controlled"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":538,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"venlafaxine ER 75 mg/day (fixed dose)","type":"EXPERIMENTAL","interventionNames":["Drug: venlafaxine ER 75 mg/day (fixed dose)"]},{"label":"venlafaxine ER 75 mg/day to 225 mg/day (flexible dose)","type":"EXPERIMENTAL","interventionNames":["Drug: venlafaxine ER 75 mg/day to 225 mg/day (flexible dose)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"venlafaxine ER 75 mg/day (fixed dose)","description":"Treatment phase: 8 weeks (37.5 mg/day for 1st week and 75 mg/day for 7 weeks), oral administration Tapering phase: 2 weeks (37.5 mg/day for the 1st week and placebo for the 2nd week), oral administration","armGroupLabels":["venlafaxine ER 75 mg/day (fixed dose)"]},{"type":"DRUG","name":"venlafaxine ER 75 mg/day to 225 mg/day (flexible dose)","description":"Treatment phase: 8 weeks (37.5 mg/day for the 1st week, 75 mg/day for the 2nd weeks, 75-150 mg for the 3rd week, 75-225 mg/day for the rest of 5 weeks), oral administration Tapering phase: 2 weeks (75/37.5 mg/day for the 1st week and 37.5 mg/day/placebo for the 2nd week), oral administration","armGroupLabels":["venlafaxine ER 75 mg/day to 225 mg/day (flexible dose)"]},{"type":"DRUG","name":"Placebo","description":"Treatment phase: 8 weeks (placebo), oral administration Tapering phase: 2 weeks (placebo), oral administration","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change From Baseline in 17-item Hamilton Raing Scale for Depression (HAM-D17) Total Score at Week 8 or Early Termination","description":"HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression (symptoms such as depressed mood, work and activities, sleep, suicide, psychomotor agitation/retardation, appetite, sexual interest, anxiety, and somatic symptoms). The items of the HAM-D17 are rated on a scale of 0 to 2 or 0 to 4, and the total score ranges from 0 to 52. Higher scores indicate more severe symptoms. Change from baseline: mean score at Week 8 or early termination minus mean score at baseline.","timeFrame":"Baseline, Week 8 or Early termination"}],"secondaryOutcomes":[{"measure":"Changes From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 8 or Early Termination","description":"MADRS is a scale used in subjects with major depressive disorder to measure the overall severity of depressive symptoms. It is a 10 item, clinician-rated scale that assesses treatment-sensitive change by evaluating ten areas of depressive symptomatology: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts. The items are rated on a 7 point Likert scale (0 - 6) with anchors at 2 point intervals. The total score ranges from 0 to 60, and higher scores indicate more severe symptoms. Change from baseline: mean score at Week 8 or early termination minus mean score at baseline.","timeFrame":"Baseline, Week 8 or Early termination"},{"measure":"Changes From Baseline in Clinical Global Impression-Severity (CGI-S) at Week 8 or Early Termination","description":"CGI-S is a 7-point clinician rated scale to assess severity of participant's current illness state; range: 1=normal, not ill at all, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=among the most extremely ill patients. Higher scores reflect higher severity of current illness states. Change from baseline: mean score at Week 8 or early termination minus mean score at baseline.","timeFrame":"Baseline, Week 8 or Early termination"},{"measure":"Changes From Baseline in 6-item Hamilton Rating Scale for Depression (HAM-D6) Total Score at Week 8 or Early Termination","description":"HAM-D6 is a subset of the HAM-D17 that assesses 6 items associated with major depression. The scale uses HAM-D17 items 1, 2, 7, 8, 10 and 13. Item 13 is scored 0 to 2 and all others are scored 0 to 4. Total score ranges from 0 to 22; higher score indicates more depression. Change from baseline: mean score at Week 8 or early termination minus mean score at baseline.","timeFrame":"Baseline, Week 8 or Early termination"},{"measure":"Changes From Baseline in 16-item Quick Inventory of Depressive Symptomatology Self-Report Japanese Version (QIDS16-SR-J) Total Score at Week 8 or Early Termination","description":"QIDS16-SR-J is a self-rated scale used in patients with major depressive disorder to measure the overall severity of depressive symptoms: 1) sad mood; 2) concentration; 3) self-criticism; 4) suicidal ideation; 5) interest; 6) energy/fatigue; 7) sleep disturbance (initial, middle, and late insomnia or hypersomnia); 8) decrease/increase in appetite/weight; and 9) psychomotor agitation/retardation. QIDS16-SR-J items are rated on a scale of 0 to 3. The total score ranges from 0 to 27, and higher scores indicate more severe symptoms. Change from baseline: mean score at Week 8 or early termination minus mean score at baseline.","timeFrame":"Baseline, Week 8 or Early termination"},{"measure":"Mean Clinical Global Impression - Improvement (CGI-I) Score at Week 8 or Early Termination","description":"CGI-I is a 7-point clinician rated scale ranging from 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, to 7=very much worse. Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Scores above 4 reflect worsening of illness state as compared to baseline.","timeFrame":"Baseline, Week 8 or Early termination"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Outpatient status.\n* A primary diagnosis of MDD based on the criteria in the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM- IV-TR), single or recurrent episode, without psychotic features.\n* Depressive symptoms for at least 90 days in single episode and for at least 28 days in recurrent episode before the screening visit.\n* A MADRS total score ≥26 at the screening and baseline visits. And change of MADRS total score at baseline is not over 25% from the screening visit.\n* A QIDS16-J-SR score ≥16 at the screening and baseline visits.\n* A score ≥4 on the Clinical Global Impressions Scale-Severity (CGI-S) at the screening and baseline visits.\n\nExclusion Criteria:\n\n* Subjects who concurrently have Axis II personality disorder or mental retardation according to DSM-IV diagnostic criteria.\n* Subjects who meet DSM-IV criteria for current or past history of Schizophrenia, Paranoid Disorders, or any other Psychotic Disorders.\n* Subjects who meet DSM-IV criteria for current or past history of Dementia.\n* Subjects who meet DSM-IV criteria for current or past history of bipolar disorder, Posttraumatic Stress Disorder (PTSD) or Obsessive Compulsive Disorder (OCD).\n* Subjects who meet DSM-IV criteria for current (within 12 months before the screening visit) generalized anxiety disorder, panic disorder, or social anxiety disorder considered by the investigator to be primary (causing a higher degree of distress or impairment than MDD).\n* Subjects with a first degree relative with bipolar disorder.\n* Subjects who are actively suicidal.\n* History of non-responsive to 2 antidepressant treatment (at least 6-week usage for each) for the past or current episodes.\n* History of Electroconvulsive therapy (ECT) at any time in the past.\n* History of chronic treatment with benzodiazepines for longer than 6 months before the screening visit (Excluding subjects who have taken PRN benzodiazepine use, \\< 3 times/week).\n* Any unstable hepatic, renal, pulmonary, cardiovascular (including uncontrolled hypertension), ophthalmologic, neurologic, or any other medical condition that in the investigator's judgment, will substantially increase the risk associated with the subject's participation in and completion of, the study.\n* Known presence of raised intraocular pressure or history or presence of narrow angle glaucoma.\n* Myocardial infarction within 180 days of the screening visit.\n* Clinically important abnormalities, as determined by the investigator, on screening physical examination, electrocardiogram (ECG) or laboratory tests.\n* Use of prohibited treatments","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Pfizer CT.gov Call Center","affiliation":"Pfizer","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Narumi Himawari Clinic","city":"Nagoya","state":"Aichi-ken","zip":"458-0801","country":"Japan","geoPoint":{"lat":35.18147,"lon":136.90641}},{"facility":"Mizuho Clinic","city":"Nagoya","state":"Aichi-ken","zip":"467-0806","country":"Japan","geoPoint":{"lat":35.18147,"lon":136.90641}},{"facility":"Nippon Medical School Chiba Hokusoh Hospital","city":"Inzai","state":"Chiba","zip":"270-1694","country":"Japan","geoPoint":{"lat":35.83479,"lon":140.16361}},{"facility":"Hida Clinic","city":"Nagareyama","state":"Chiba","zip":"270-0163","country":"Japan","geoPoint":{"lat":35.8563,"lon":139.90266}},{"facility":"Nakamoto Clinic","city":"Noda","state":"Chiba","zip":"278-0033","country":"Japan","geoPoint":{"lat":35.94897,"lon":139.86793}},{"facility":"Hatsuki Shinryo Clinic","city":"Fukuoka","state":"Fukuoka","zip":"814-0104","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}},{"facility":"Hatakeyama Clinic","city":"Kitakyushu-shi","state":"Fukuoka","zip":"802-0064","country":"Japan"},{"facility":"Shiranui Hospital","city":"Omuta","state":"Fukuoka","zip":"836-0004","country":"Japan","geoPoint":{"lat":33.03333,"lon":130.45}},{"facility":"Oka Clinic","city":"Omuta","state":"Fukuoka","zip":"836-0044","country":"Japan","geoPoint":{"lat":33.03333,"lon":130.45}},{"facility":"Fujikawa Clinic","city":"Hatsukaichi","state":"Hiroshima","zip":"738-0023","country":"Japan","geoPoint":{"lat":34.35,"lon":132.33333}},{"facility":"Hayakawa Clinic","city":"Kure","state":"Hiroshima","zip":"737-0111","country":"Japan","geoPoint":{"lat":34.23222,"lon":132.56658}},{"facility":"Kawamura Mental Clinic","city":"Sapporo","state":"Hokkaido","zip":"001-0023","country":"Japan","geoPoint":{"lat":43.06667,"lon":141.35}},{"facility":"Maruyamapark Mentalclinic","city":"Sapporo","state":"Hokkaido","zip":"064-0820","country":"Japan","geoPoint":{"lat":43.06667,"lon":141.35}},{"facility":"Arai Clinic","city":"Amagasaki","state":"Hyōgo","zip":"660-0882","country":"Japan","geoPoint":{"lat":34.71667,"lon":135.41667}},{"facility":"Takahashi Psychiatric Clinic","city":"Ashiya","state":"Hyōgo","zip":"659-0093","country":"Japan","geoPoint":{"lat":34.72807,"lon":135.30264}},{"facility":"Tatsuta Clinic","city":"Kobe","state":"Hyōgo","zip":"651-0097","country":"Japan","geoPoint":{"lat":34.6913,"lon":135.183}},{"facility":"Ikeuchi Psycho Induced Internal Med.Clinic","city":"Kobe","state":"Hyōgo","zip":"655-0037","country":"Japan","geoPoint":{"lat":34.6913,"lon":135.183}},{"facility":"National Hospital Organization Kanazawa Medical Center","city":"Kanazawa","state":"Ishikawa-ken","zip":"920-8650","country":"Japan","geoPoint":{"lat":36.6,"lon":136.61667}},{"facility":"Medical Corporation Seishinkai Kishiro Mental Clinic","city":"Kawasaki","state":"Kanagawa","zip":"214-0014","country":"Japan","geoPoint":{"lat":35.52056,"lon":139.71722}},{"facility":"Yutaka Clinic","city":"Sagamihara","state":"Kanagawa","zip":"252-0303","country":"Japan","geoPoint":{"lat":35.56707,"lon":139.24167}},{"facility":"Azamino Mental Clinic","city":"Yokohama","state":"Kanagawa","zip":"225-0011","country":"Japan","geoPoint":{"lat":35.43333,"lon":139.65}},{"facility":"Shioiri Mental Clinic","city":"Yokosuka","state":"Kanagawa","zip":"238-0042","country":"Japan","geoPoint":{"lat":35.28361,"lon":139.66722}},{"facility":"Yuge Hospital","city":"Kumamoto","state":"Kumamoto","zip":"861-8002","country":"Japan","geoPoint":{"lat":32.80589,"lon":130.69181}},{"facility":"Kuginuki Clinic","city":"Hirakata","state":"Osaka","zip":"573-0032","country":"Japan","geoPoint":{"lat":34.81352,"lon":135.64914}},{"facility":"Shibamoto Clinic","city":"Osakasayama-shi","state":"Osaka","zip":"589-0011","country":"Japan"},{"facility":"Sakai Mental Clinic","city":"Saitama","state":"Saitama","zip":"330-0062","country":"Japan","geoPoint":{"lat":35.90807,"lon":139.65657}},{"facility":"Suzuki Hospital","city":"Adachi-ku","state":"Tokyo","zip":"120-0033","country":"Japan"},{"facility":"Iidabashi Mental Clinic","city":"Chiyoda-ku","state":"Tokyo","zip":"102-0071","country":"Japan"},{"facility":"Tutujigaoka Mental Clinic","city":"Chōfu","state":"Tokyo","zip":"182-0006","country":"Japan","geoPoint":{"lat":35.65924,"lon":139.54837}},{"facility":"Fuku Clinic","city":"Katsushika-ku","state":"Tokyo","zip":"125-0041","country":"Japan","geoPoint":{"lat":35.73333,"lon":139.85}},{"facility":"SAKURAZAKA CLINIC SophyAnce","city":"Minato-ku","state":"Tokyo","zip":"106-0032","country":"Japan"},{"facility":"Akasaka Clinic","city":"Minato-ku","state":"Tokyo","zip":"107-0052","country":"Japan"},{"facility":"Harikae mental clinic","city":"Nakano-Ku","state":"Tokyo","zip":"164-0001","country":"Japan"},{"facility":"Heartcare Ginga Clinic","city":"Nakano-ku","state":"Tokyo","zip":"164-0012","country":"Japan"},{"facility":"Sangenjaya Nakamura Mental Clinic","city":"Setagaya-ku","state":"Tokyo","zip":"154-0004","country":"Japan"},{"facility":"Komazawa Mental Clinic","city":"Setagaya-ku","state":"Tokyo","zip":"154-0012","country":"Japan"},{"facility":"Omotesando Mental Clinic","city":"Shibuya-ku","state":"Tokyo","zip":"150-0001","country":"Japan"},{"facility":"Maynds Tower Mental Clinic","city":"Shibuya-ku","state":"Tokyo","zip":"151-0053","country":"Japan"},{"facility":"Yoyoginomori Mental Clinic","city":"Shibuyaku","state":"Tokyo","zip":"151-0053","country":"Japan"},{"facility":"Meguro sta.East Mental Clinic","city":"Shinagawa-ku","state":"Tokyo","zip":"141-0021","country":"Japan"},{"facility":"Himeno Tomomi Clinic","city":"Shinagawa-Ku","state":"Tokyo","zip":"141-0032","country":"Japan"},{"facility":"Nishi-Shinjuku Concieria Clinic","city":"Shinjuku-ku","state":"Tokyo","zip":"160-0023","country":"Japan"},{"facility":"Tamaki Clinic","city":"Shinjuku-ku","state":"Tokyo","zip":"160-0023","country":"Japan"},{"facility":"Kagurazaka Stress Clinic","city":"Shinjuku-ku","state":"Tokyo","zip":"162-0825","country":"Japan"},{"facility":"Tokyo Kosei Nenkin Hospital","city":"Shinjuku-ku","state":"Tokyo","zip":"162-8543","country":"Japan"},{"facility":"Tokyo Women's Medical University Hospital","city":"Shinjuku-ku","state":"Tokyo","zip":"162-8666","country":"Japan"},{"facility":"Himorogi Psychiatric Institute","city":"Toshima-ku","state":"Tokyo","zip":"170-0002","country":"Japan"},{"facility":"Sugahara Tenjin Clinic","city":"Fukuoka","zip":"810-0001","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}},{"facility":"Hiro Mental Clinic Tenjinminami","city":"Fukuoka","zip":"810-0004","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}},{"facility":"Tenjin Mental Clinic","city":"Fukuoka","zip":"810-0004","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}},{"facility":"Medical Corporation Shinseikai Kaku Mental Clinic","city":"Fukuoka","zip":"810-0022","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}},{"facility":"Ange Psychiatric Clinic","city":"Fukuoka","zip":"810-0035","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}},{"facility":"Stress Care Yoshimura Clinic","city":"Fukuoka","zip":"810-0041","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}},{"facility":"Kuranari Psychiatry Clinic","city":"Fukuoka","zip":"810-0801","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}},{"facility":"Akasaka Kato Clinic","city":"Fukuoka","zip":"8100041","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}},{"facility":"Imato Clinic","city":"Fukuoka","zip":"815-0041","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}},{"facility":"Tsuji Mental Clinic","city":"Hiroshima","zip":"731-0112","country":"Japan","geoPoint":{"lat":34.4,"lon":132.45}},{"facility":"Medical Corporation Toyokokai Tawara Clinic","city":"Kanagawa","zip":"221-0835","country":"Japan","geoPoint":{"lat":37.58333,"lon":139.91667}},{"facility":"Sagaarashiyama-Tanaka Clinic","city":"Kyoto","zip":"616-8421","country":"Japan","geoPoint":{"lat":35.02107,"lon":135.75385}},{"facility":"Kyo Mental Clinic","city":"Nara","zip":"631-0036","country":"Japan","geoPoint":{"lat":34.68505,"lon":135.80485}},{"facility":"JIN clinic","city":"Osaka","zip":"530-0041","country":"Japan","geoPoint":{"lat":34.69379,"lon":135.50107}},{"facility":"Misato Ekimae Clinic","city":"Saitama","zip":"341-0018","country":"Japan","geoPoint":{"lat":35.90807,"lon":139.65657}},{"facility":"Eto Mental Clinic Meguro","city":"Tokyo","zip":"142-0021","country":"Japan","geoPoint":{"lat":35.6895,"lon":139.69171}}]},"referencesModule":{"references":[{"pmid":"32912597","type":"DERIVED","citation":"Kato M, Asami Y, Wajsbrot DB, Wang X, Boucher M, Prieto R, Pappadopulos E. Clustering patients by depression symptoms to predict venlafaxine ER antidepressant efficacy: Individual patient data analysis. J Psychiatr Res. 2020 Oct;129:160-167. doi: 10.1016/j.jpsychires.2020.06.011. Epub 2020 Jul 9."},{"pmid":"26513202","type":"DERIVED","citation":"Higuchi T, Kamijima K, Nakagome K, Itamura R, Asami Y, Kuribayashi K, Imaeda T. A randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of venlafaxine extended release and a long-term extension study for patients with major depressive disorder in Japan. Int Clin Psychopharmacol. 2016 Jan;31(1):8-19. doi: 10.1097/YIC.0000000000000105."}],"seeAlsoLinks":[{"label":"To obtain contact information for a study center near you, click here.","url":"https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B2411263&StudyName=Venlafaxine%20ER%20Phase%203%20Study%20for%20Major%20Depressive%20Disorder%20%28MDD%29"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Subjects were confirmed to meet entry criteria at the screening visit, followed by a 2-week screening period. Subjects who continued to meet all study entry criteria at baseline were randomized to 10 weeks of treatment with placebo, venlafaxine ER 75 mg/day Fixed, or venlafaxine ER 75-225 mg/day Flexible in the ratio of 1:1:1.","groups":[{"id":"FG000","title":"Placebo","description":"Participants received placebo capsule orally once daily after meal for 8 weeks."},{"id":"FG001","title":"Venlafaxine 75 mg/Day Fixed","description":"Participants received venlafaxine ER capsule orally once daily after meal for 8 weeks. Starting dose was 37.5 mg/day followed by 75 mg/day at Week 1. If there was no tolerability concern at Week 2, the dose was continued 75 mg/day until Week 8."},{"id":"FG002","title":"Venlafaxine 75-225 mg/Day Flexible","description":"Participants received venlafaxine ER capsule orally once daily after meal for 8 weeks. Starting dose was 37.5 mg/day followed by 75 mg/day at Week 1. If there was no tolerability concern at Week 2, the dose was increased to 150 mg/day. If there was no tolerability concern at Week 3, the dose was increased to 225 mg/day. Dose was reduced in the case of intolerability and if the participants could not take venlafaxine 75 mg/day or higher doses at Week 1 and the following weeks, the treatment were discontinued. No dose adjustment was allowed from Week 4 to Week 8."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","comment":"Safety analysis set","numSubjects":"183"},{"groupId":"FG001","comment":"Safety analysis set","numSubjects":"174"},{"groupId":"FG002","comment":"Safety analysis set","numSubjects":"180"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"166"},{"groupId":"FG001","numSubjects":"151"},{"groupId":"FG002","numSubjects":"158"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"17"},{"groupId":"FG001","numSubjects":"23"},{"groupId":"FG002","numSubjects":"22"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"9"},{"groupId":"FG002","numSubjects":"9"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"9"},{"groupId":"FG002","numSubjects":"9"}]},{"type":"Pregnancy","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Moving","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Work-related matter","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Difficllty in keeping the schedule","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Placebo","description":"Participants received placebo capsule orally once daily after meal for 8 weeks."},{"id":"BG001","title":"Venlafaxine 75 mg/Day Fixed","description":"Participants received venlafaxine ER capsule orally once daily after meal for 8 weeks. Starting dose was 37.5 mg/day followed by 75 mg/day at Week 1. If there was no tolerability concern at Week 2, the dose was continued 75 mg/day until Week 8."},{"id":"BG002","title":"Venlafaxine 75-225 mg/Day Flexible","description":"Participants received venlafaxine ER capsule orally once daily after meal for 8 weeks. Starting dose was 37.5 mg/day followed by 75 mg/day at Week 1. If there was no tolerability concern at Week 2, the dose was increased to 150 mg/day. If there was no tolerability concern at Week 3, the dose was increased to 225 mg/day. Dose was reduced in the case of intolerability and if the participants could not take venlafaxine 75 mg/day or higher doses at Week 1 and the following weeks, the treatment were discontinued. No dose adjustment was allowed from Week 4 to Week 8."},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"184"},{"groupId":"BG001","value":"174"},{"groupId":"BG002","value":"179"},{"groupId":"BG003","value":"537"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"38.6","spread":"11.1"},{"groupId":"BG001","value":"38.4","spread":"11.9"},{"groupId":"BG002","value":"38.3","spread":"10.2"},{"groupId":"BG003","value":"38.4","spread":"11.1"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"FEMALE","measurements":[{"groupId":"BG000","value":"93"},{"groupId":"BG001","value":"90"},{"groupId":"BG002","value":"86"},{"groupId":"BG003","value":"269"}]},{"title":"MALE","measurements":[{"groupId":"BG000","value":"91"},{"groupId":"BG001","value":"84"},{"groupId":"BG002","value":"93"},{"groupId":"BG003","value":"268"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in 17-item Hamilton Raing Scale for Depression (HAM-D17) Total Score at Week 8 or Early Termination","description":"HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression (symptoms such as depressed mood, work and activities, sleep, suicide, psychomotor agitation/retardation, appetite, sexual interest, anxiety, and somatic symptoms). The items of the HAM-D17 are rated on a scale of 0 to 2 or 0 to 4, and the total score ranges from 0 to 52. Higher scores indicate more severe symptoms. Change from baseline: mean score at Week 8 or early termination minus mean score at baseline.","populationDescription":"Participants randomly assigned to treatment who took at least one dose of the study drug in the double-blind period and who had both baseline and at least one post-baseline measurements of the primary efficacy variable.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"Units on a scale","timeFrame":"Baseline, Week 8 or Early termination","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo capsule orally once daily after meal for 8 weeks."},{"id":"OG001","title":"Venlafaxine 75 mg/Day Fixed","description":"Participants received venlafaxine ER capsule orally once daily after meal for 8 weeks. Starting dose was 37.5 mg/day followed by 75 mg/day at Week 1. If there was no tolerability concern at Week 2, the dose was continued 75 mg/day until Week 8."},{"id":"OG002","title":"Venlafaxine 75-225 mg/Day Flexible","description":"Participants received venlafaxine ER capsule orally once daily after meal for 8 weeks. Starting dose was 37.5 mg/day followed by 75 mg/day at Week 1. If there was no tolerability concern at Week 2, the dose was increased to 150 mg/day. If there was no tolerability concern at Week 3, the dose was increased to 225 mg/day. Dose was reduced in the case of intolerability and if the participants could not take venlafaxine 75 mg/day or higher doses at Week 1 and the following weeks, the treatment were discontinued. No dose adjustment was allowed from Week 4 to Week 8."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"184"},{"groupId":"OG001","value":"174"},{"groupId":"OG002","value":"177"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.25","spread":"0.48"},{"groupId":"OG001","value":"-10.76","spread":"0.50"},{"groupId":"OG002","value":"-10.37","spread":"0.49"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.031","pValueComment":"Two-sided p-value from an analysis of covariance model including treatment as a factor and baseline as a covariate.","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"1.50","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.14","ciUpperLimit":"2.87","estimateComment":"Adjusted mean difference = Placebo group - Venlafaxine 75 mg/day Fixed group"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.106","pValueComment":"Two-sided p-value from an analysis of covariance model including treatment as a factor and baseline as a covariate.","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"1.12","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.24","ciUpperLimit":"2.48","estimateComment":"Adjusted mean difference = Placebo group - Venlafaxine 75-225 mg/day Flexible group"}]},{"type":"SECONDARY","title":"Changes From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 8 or Early Termination","description":"MADRS is a scale used in subjects with major depressive disorder to measure the overall severity of depressive symptoms. It is a 10 item, clinician-rated scale that assesses treatment-sensitive change by evaluating ten areas of depressive symptomatology: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts. The items are rated on a 7 point Likert scale (0 - 6) with anchors at 2 point intervals. The total score ranges from 0 to 60, and higher scores indicate more severe symptoms. Change from baseline: mean score at Week 8 or early termination minus mean score at baseline.","populationDescription":"Participants randomly assigned to treatment who took at least one dose of the study drug in the double-blind period and who had both baseline and at least one post-baseline measurements of the primary efficacy variable.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"Units on a scale","timeFrame":"Baseline, Week 8 or Early termination","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo capsule orally once daily after meal for 8 weeks."},{"id":"OG001","title":"Venlafaxine 75 mg/Day Fixed","description":"Participants received venlafaxine ER capsule orally once daily after meal for 8 weeks. Starting dose was 37.5 mg/day followed by 75 mg/day at Week 1. If there was no tolerability concern at Week 2, the dose was continued 75 mg/day until Week 8."},{"id":"OG002","title":"Venlafaxine 75-225 mg/Day Flexible","description":"Participants received venlafaxine ER capsule orally once daily after meal for 8 weeks. Starting dose was 37.5 mg/day followed by 75 mg/day at Week 1. If there was no tolerability concern at Week 2, the dose was increased to 150 mg/day. If there was no tolerability concern at Week 3, the dose was increased to 225 mg/day. Dose was reduced in the case of intolerability and if the participants could not take venlafaxine 75 mg/day or higher doses at Week 1 and the following weeks, the treatment were discontinued. No dose adjustment was allowed from Week 4 to Week 8."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"172"},{"groupId":"OG002","value":"176"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.41","spread":"0.75"},{"groupId":"OG001","value":"-15.30","spread":"0.77"},{"groupId":"OG002","value":"-15.05","spread":"0.76"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.008","pValueComment":"Two-sided p-value from an analysis of covariance model including treatment as a factor and baseline as a covariate.","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"2.88","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.77","ciUpperLimit":"5.00","estimateComment":"Adjusted mean difference = Placebo group - Venlafaxine 75 mg/day Fixed group"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.014","pValueComment":"Two-sided p-value from an analysis of covariance model including treatment as a factor and baseline as a covariate.","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"2.64","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.54","ciUpperLimit":"4.74","estimateComment":"Adjusted mean difference = Placebo group - Venlafaxine 75-225 mg/day Flexible group"}]},{"type":"SECONDARY","title":"Changes From Baseline in Clinical Global Impression-Severity (CGI-S) at Week 8 or Early Termination","description":"CGI-S is a 7-point clinician rated scale to assess severity of participant's current illness state; range: 1=normal, not ill at all, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=among the most extremely ill patients. Higher scores reflect higher severity of current illness states. Change from baseline: mean score at Week 8 or early termination minus mean score at baseline.","populationDescription":"Participants randomly assigned to treatment who took at least one dose of the study drug in the double-blind period and who had both baseline and at least one post-baseline measurements of the primary efficacy variable.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"Units on a scale","timeFrame":"Baseline, Week 8 or Early termination","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo capsule orally once daily after meal for 8 weeks."},{"id":"OG001","title":"Venlafaxine 75 mg/Day Fixed","description":"Participants received venlafaxine ER capsule orally once daily after meal for 8 weeks. Starting dose was 37.5 mg/day followed by 75 mg/day at Week 1. If there was no tolerability concern at Week 2, the dose was continued 75 mg/day until Week 8."},{"id":"OG002","title":"Venlafaxine 75-225 mg/Day Flexible","description":"Participants received venlafaxine ER capsule orally once daily after meal for 8 weeks. Starting dose was 37.5 mg/day followed by 75 mg/day at Week 1. If there was no tolerability concern at Week 2, the dose was increased to 150 mg/day. If there was no tolerability concern at Week 3, the dose was increased to 225 mg/day. Dose was reduced in the case of intolerability and if the participants could not take venlafaxine 75 mg/day or higher doses at Week 1 and the following weeks, the treatment were discontinued. No dose adjustment was allowed from Week 4 to Week 8."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"184"},{"groupId":"OG001","value":"174"},{"groupId":"OG002","value":"177"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.31","spread":"0.08"},{"groupId":"OG001","value":"-1.57","spread":"0.08"},{"groupId":"OG002","value":"-1.56","spread":"0.08"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.025","pValueComment":"Two-sided p-value from an analysis of covariance model including treatment as a factor and baseline as a covariate.","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"0.26","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.03","ciUpperLimit":"0.49","estimateComment":"Adjusted mean difference = Placebo group - Venlafaxine 75 mg/day Fixed group"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.032","pValueComment":"Two-sided p-value from an analysis of covariance model including treatment as a factor and baseline as a covariate.","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"0.25","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.02","ciUpperLimit":"0.48","estimateComment":"Adjusted mean difference = Placebo group - Venlafaxine 75-225 mg/day Flexible group"}]},{"type":"SECONDARY","title":"Changes From Baseline in 6-item Hamilton Rating Scale for Depression (HAM-D6) Total Score at Week 8 or Early Termination","description":"HAM-D6 is a subset of the HAM-D17 that assesses 6 items associated with major depression. The scale uses HAM-D17 items 1, 2, 7, 8, 10 and 13. Item 13 is scored 0 to 2 and all others are scored 0 to 4. Total score ranges from 0 to 22; higher score indicates more depression. Change from baseline: mean score at Week 8 or early termination minus mean score at baseline.","populationDescription":"Participants randomly assigned to treatment who took at least one dose of the study drug in the double-blind period and who had both baseline and at least one post-baseline measurements of the primary efficacy variable.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"Units on a scale","timeFrame":"Baseline, Week 8 or Early termination","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo capsule orally once daily after meal for 8 weeks."},{"id":"OG001","title":"Venlafaxine 75 mg/Day Fixed","description":"Participants received venlafaxine ER capsule orally once daily after meal for 8 weeks. Starting dose was 37.5 mg/day followed by 75 mg/day at Week 1. If there was no tolerability concern at Week 2, the dose was continued 75 mg/day until Week 8."},{"id":"OG002","title":"Venlafaxine 75-225 mg/Day Flexible","description":"Participants received venlafaxine ER capsule orally once daily after meal for 8 weeks. Starting dose was 37.5 mg/day followed by 75 mg/day at Week 1. If there was no tolerability concern at Week 2, the dose was increased to 150 mg/day. If there was no tolerability concern at Week 3, the dose was increased to 225 mg/day. Dose was reduced in the case of intolerability and if the participants could not take venlafaxine 75 mg/day or higher doses at Week 1 and the following weeks, the treatment were discontinued. No dose adjustment was allowed from Week 4 to Week 8."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"184"},{"groupId":"OG001","value":"174"},{"groupId":"OG002","value":"177"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.92","spread":"0.28"},{"groupId":"OG001","value":"-6.10","spread":"0.29"},{"groupId":"OG002","value":"-5.99","spread":"0.29"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.004","pValueComment":"Two-sided p-value from an analysis of covariance model including treatment as a factor and baseline as a covariate.","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"1.18","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.39","ciUpperLimit":"1.97","estimateComment":"Adjusted mean difference = Placebo group - Venlafaxine 75 mg/day Fixed group"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.008","pValueComment":"Two-sided p-value from an analysis of covariance model including treatment as a factor and baseline as a covariate.","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"1.06","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.28","ciUpperLimit":"1.85","estimateComment":"Adjusted mean difference = Placebo group - Venlafaxine 75-225 mg/day Flexible group"}]},{"type":"SECONDARY","title":"Changes From Baseline in 16-item Quick Inventory of Depressive Symptomatology Self-Report Japanese Version (QIDS16-SR-J) Total Score at Week 8 or Early Termination","description":"QIDS16-SR-J is a self-rated scale used in patients with major depressive disorder to measure the overall severity of depressive symptoms: 1) sad mood; 2) concentration; 3) self-criticism; 4) suicidal ideation; 5) interest; 6) energy/fatigue; 7) sleep disturbance (initial, middle, and late insomnia or hypersomnia); 8) decrease/increase in appetite/weight; and 9) psychomotor agitation/retardation. QIDS16-SR-J items are rated on a scale of 0 to 3. The total score ranges from 0 to 27, and higher scores indicate more severe symptoms. Change from baseline: mean score at Week 8 or early termination minus mean score at baseline.","populationDescription":"Participants randomly assigned to treatment who took at least one dose of the study drug in the double-blind period and who had both baseline and at least one post-baseline measurements of the primary efficacy variable.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"Units on a scale","timeFrame":"Baseline, Week 8 or Early termination","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo capsule orally once daily after meal for 8 weeks."},{"id":"OG001","title":"Venlafaxine 75 mg/Day Fixed","description":"Participants received venlafaxine ER capsule orally once daily after meal for 8 weeks. Starting dose was 37.5 mg/day followed by 75 mg/day at Week 1. If there was no tolerability concern at Week 2, the dose was continued 75 mg/day until Week 8."},{"id":"OG002","title":"Venlafaxine 75-225 mg/Day Flexible","description":"Participants received venlafaxine ER capsule orally once daily after meal for 8 weeks. Starting dose was 37.5 mg/day followed by 75 mg/day at Week 1. If there was no tolerability concern at Week 2, the dose was increased to 150 mg/day. If there was no tolerability concern at Week 3, the dose was increased to 225 mg/day. Dose was reduced in the case of intolerability and if the participants could not take venlafaxine 75 mg/day or higher doses at Week 1 and the following weeks, the treatment were discontinued. No dose adjustment was allowed from Week 4 to Week 8."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"172"},{"groupId":"OG002","value":"175"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.50","spread":"0.36"},{"groupId":"OG001","value":"-8.00","spread":"0.37"},{"groupId":"OG002","value":"-7.27","spread":"0.37"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.004","pValueComment":"Two-sided p-value from an analysis of covariance model including treatment as a factor and baseline as a covariate.","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"1.50","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.48","ciUpperLimit":"2.53","estimateComment":"Adjusted mean difference = Placebo group - Venlafaxine 75 mg/day Fixed group"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.137","pValueComment":"Two-sided p-value from an analysis of covariance model including treatment as a factor and baseline as a covariate.","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"0.77","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.25","ciUpperLimit":"1.79","estimateComment":"Adjusted mean difference = Placebo group - Venlafaxine 75-225 mg/day Flexible group"}]},{"type":"SECONDARY","title":"Mean Clinical Global Impression - Improvement (CGI-I) Score at Week 8 or Early Termination","description":"CGI-I is a 7-point clinician rated scale ranging from 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, to 7=very much worse. Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Scores above 4 reflect worsening of illness state as compared to baseline.","populationDescription":"Participants randomly assigned to treatment who took at least one dose of the study drug in the double-blind period and who had both baseline and at least one post-baseline measurements of the primary efficacy variable.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"Units on a scale","timeFrame":"Baseline, Week 8 or Early termination","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo capsule orally once daily after meal for 8 weeks."},{"id":"OG001","title":"Venlafaxine 75 mg/Day Fixed","description":"Participants received venlafaxine ER capsule orally once daily after meal for 8 weeks. Starting dose was 37.5 mg/day followed by 75 mg/day at Week 1. If there was no tolerability concern at Week 2, the dose was continued 75 mg/day until Week 8."},{"id":"OG002","title":"Venlafaxine 75-225 mg/Day Flexible","description":"Participants received venlafaxine ER capsule orally once daily after meal for 8 weeks. Starting dose was 37.5 mg/day followed by 75 mg/day at Week 1. If there was no tolerability concern at Week 2, the dose was increased to 150 mg/day. If there was no tolerability concern at Week 3, the dose was increased to 225 mg/day. Dose was reduced in the case of intolerability and if the participants could not take venlafaxine 75 mg/day or higher doses at Week 1 and the following weeks, the treatment were discontinued. No dose adjustment was allowed from Week 4 to Week 8."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"184"},{"groupId":"OG001","value":"174"},{"groupId":"OG002","value":"177"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.53","spread":"0.08"},{"groupId":"OG001","value":"2.32","spread":"0.09"},{"groupId":"OG002","value":"2.28","spread":"0.08"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.073","pValueComment":"Two-sided p-value from an analysis of covariance model including treatment as a factor and baseline score of CGI-S as a covariate.","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"0.21","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.02","ciUpperLimit":"0.45","estimateComment":"Adjusted mean difference = Placebo group - Venlafaxine 75 mg/day Fixed group"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.034","pValueComment":"Two-sided p-value from an analysis of covariance model including treatment as a factor and baseline score of CGI-S as a covariate.","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"0.25","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.02","ciUpperLimit":"0.48","estimateComment":"Adjusted mean difference = Placebo group - Venlafaxine 75-225 mg/day Flexible group"}]}]},"adverseEventsModule":{"frequencyThreshold":"2","eventGroups":[{"id":"EG000","title":"Placebo","description":"Participants received placebo capsule orally once daily after meal for 8 weeks.","seriousNumAffected":2,"seriousNumAtRisk":183,"otherNumAffected":98,"otherNumAtRisk":183},{"id":"EG001","title":"Venlafaxine 75 mg/Day Fixed","description":"Participants received venlafaxine ER capsule orally once daily after meal for 8 weeks. Starting dose was 37.5 mg/day followed by 75 mg/day at Week 1. If there was no tolerability concern at Week 2, the dose was continued 75 mg/day until Week 8.","seriousNumAffected":1,"seriousNumAtRisk":174,"otherNumAffected":112,"otherNumAtRisk":174},{"id":"EG002","title":"Venlafaxine 75-225 mg/Day Flexible","description":"Participants received venlafaxine ER capsule orally once daily after meal for 8 weeks. Starting dose was 37.5 mg/day followed by 75 mg/day at Week 1. If there was no tolerability concern at Week 2, the dose was increased to 150 mg/day. If there was no tolerability concern at Week 3, the dose was increased to 225 mg/day. Dose was reduced in the case of intolerability and if the participants could not take venlafaxine 75 mg/day or higher doses at Week 1 and the following weeks, the treatment were discontinued. No dose adjustment was allowed from Week 4 to Week 8.","seriousNumAffected":1,"seriousNumAtRisk":180,"otherNumAffected":131,"otherNumAtRisk":180}],"seriousEvents":[{"term":"Meniere's disease","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":183},{"groupId":"EG001","numAffected":1,"numAtRisk":174},{"groupId":"EG002","numAffected":0,"numAtRisk":180}]},{"term":"Completed suicide","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":183},{"groupId":"EG001","numAffected":0,"numAtRisk":174},{"groupId":"EG002","numAffected":1,"numAtRisk":180}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":183},{"groupId":"EG001","numAffected":0,"numAtRisk":174},{"groupId":"EG002","numAffected":0,"numAtRisk":180}]}],"otherEvents":[{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":183},{"groupId":"EG001","numAffected":8,"numAtRisk":174},{"groupId":"EG002","numAffected":6,"numAtRisk":180}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":183},{"groupId":"EG001","numAffected":4,"numAtRisk":174},{"groupId":"EG002","numAffected":7,"numAtRisk":180}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":183},{"groupId":"EG001","numAffected":4,"numAtRisk":174},{"groupId":"EG002","numAffected":6,"numAtRisk":180}]},{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":183},{"groupId":"EG001","numAffected":7,"numAtRisk":174},{"groupId":"EG002","numAffected":11,"numAtRisk":180}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":183},{"groupId":"EG001","numAffected":5,"numAtRisk":174},{"groupId":"EG002","numAffected":0,"numAtRisk":180}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":183},{"groupId":"EG001","numAffected":17,"numAtRisk":174},{"groupId":"EG002","numAffected":17,"numAtRisk":180}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":183},{"groupId":"EG001","numAffected":6,"numAtRisk":174},{"groupId":"EG002","numAffected":8,"numAtRisk":180}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":183},{"groupId":"EG001","numAffected":5,"numAtRisk":174},{"groupId":"EG002","numAffected":7,"numAtRisk":180}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":24,"numAtRisk":183},{"groupId":"EG001","numAffected":39,"numAtRisk":174},{"groupId":"EG002","numAffected":53,"numAtRisk":180}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":183},{"groupId":"EG001","numAffected":5,"numAtRisk":174},{"groupId":"EG002","numAffected":4,"numAtRisk":180}]},{"term":"Feeling abnormal","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":183},{"groupId":"EG001","numAffected":2,"numAtRisk":174},{"groupId":"EG002","numAffected":4,"numAtRisk":180}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":183},{"groupId":"EG001","numAffected":9,"numAtRisk":174},{"groupId":"EG002","numAffected":11,"numAtRisk":180}]},{"term":"Thirst","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":183},{"groupId":"EG001","numAffected":11,"numAtRisk":174},{"groupId":"EG002","numAffected":18,"numAtRisk":180}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":41,"numAtRisk":183},{"groupId":"EG001","numAffected":35,"numAtRisk":174},{"groupId":"EG002","numAffected":32,"numAtRisk":180}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":183},{"groupId":"EG001","numAffected":4,"numAtRisk":174},{"groupId":"EG002","numAffected":2,"numAtRisk":180}]},{"term":"Blood pressure increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":183},{"groupId":"EG001","numAffected":4,"numAtRisk":174},{"groupId":"EG002","numAffected":5,"numAtRisk":180}]},{"term":"Heart rate increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":183},{"groupId":"EG001","numAffected":10,"numAtRisk":174},{"groupId":"EG002","numAffected":13,"numAtRisk":180}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":183},{"groupId":"EG001","numAffected":4,"numAtRisk":174},{"groupId":"EG002","numAffected":4,"numAtRisk":180}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":183},{"groupId":"EG001","numAffected":10,"numAtRisk":174},{"groupId":"EG002","numAffected":18,"numAtRisk":180}]},{"term":"Dizziness postural","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":183},{"groupId":"EG001","numAffected":2,"numAtRisk":174},{"groupId":"EG002","numAffected":5,"numAtRisk":180}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":183},{"groupId":"EG001","numAffected":16,"numAtRisk":174},{"groupId":"EG002","numAffected":18,"numAtRisk":180}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":183},{"groupId":"EG001","numAffected":21,"numAtRisk":174},{"groupId":"EG002","numAffected":31,"numAtRisk":180}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":183},{"groupId":"EG001","numAffected":4,"numAtRisk":174},{"groupId":"EG002","numAffected":8,"numAtRisk":180}]},{"term":"Pollakiuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":183},{"groupId":"EG001","numAffected":2,"numAtRisk":174},{"groupId":"EG002","numAffected":5,"numAtRisk":180}]},{"term":"Hyperhidrosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":183},{"groupId":"EG001","numAffected":3,"numAtRisk":174},{"groupId":"EG002","numAffected":15,"numAtRisk":180}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results."},"pointOfContact":{"title":"Pfizer ClinicalTrials.gov Call Center","organization":"Pfizer, Inc.","email":"ClinicalTrials.gov_Inuiries@pfizer.com","phone":"1-800-718-1021"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-13"},"conditionBrowseModule":{"meshes":[{"id":"D003865","term":"Depressive Disorder, Major"}],"ancestors":[{"id":"D003866","term":"Depressive Disorder"},{"id":"D019964","term":"Mood Disorders"},{"id":"D001523","term":"Mental Disorders"}]}},"hasResults":true}